Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot second-line therapy for acquired aplastic anemia with antithymocyte globulin, cyclosporin and etanercept
2009-012746-23Phase 2Active
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jun 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of etanercept in acquired aplastic anemia (AAA) and aplastic anemia, sponsored by Istituto Giannina Gaslini. Primary endpoints: Activity and safety of etanercept in association with immunosuppressive therapy and Hematological response. Started Jun 2009; status: active.
02
Drugs
etanercept
03
Conditions
acquired aplastic anemia (AAA)aplastic anemia
Beyond the preview
Go deeper on 2009-012746-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012746-23.